The immune responsiveness upon Chek2 inhibition/depletion shows association with enhanced antigen presentation and increased type I interferon response manifested by low Chek2 expressing tumor cells in preclinical models and in human GBM scRNA-seq datasets. The gene discussed is CHEK2; the disease is neoplasm.